Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma-like fibrosing disorders.

Francesco Boin1, Laura K Hummers

  • 1Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Room 405, Baltimore, MD 21224, USA. fboin1@jhmi.edu

Rheumatic Diseases Clinics of North America
|March 11, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrosing myopathy in systemic sclerosis: Treatment response and clinical outcomes in a distinct subset.

Seminars in arthritis and rheumatism·2026
Same author

The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosis.

Rheumatology (Oxford, England)·2026
Same author

Validity and reliability of hand-held dynamometry for proximal strength assessment in systemic sclerosis-associated myopathy.

Seminars in arthritis and rheumatism·2026
Same author

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis.

Arthritis care & research·2026
Same author

Increased Xanthine Oxidoreductase Activity in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

CHEST pulmonary·2026
Same author

A CD57+CD8+ T cell subset links T cell cytotoxicity to fibrotic lung disease in systemic sclerosis.

The Journal of clinical investigation·2026
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Differentiating hard skin conditions from systemic sclerosis is crucial for effective patient management. Recognizing conditions like nephrogenic systemic fibrosis and eosinophilic fasciitis prevents ineffective treatments.

Area of Science:

  • Dermatology
  • Rheumatology
  • Internal Medicine

Background:

  • Systemic sclerosis (scleroderma) shares clinical features with other fibrotic skin disorders.
  • Diverse etiologies and unclear pathogenesis complicate differential diagnosis.
  • Accurate diagnosis is vital to avoid ineffective treatments and ensure proper patient management.

Purpose of the Study:

  • To differentiate scleroderma from other conditions causing hard skin and tissue fibrosis.
  • To highlight key distinguishing features of specific fibrotic disorders.
  • To emphasize the importance of prompt diagnosis for rheumatologists and primary care physicians.

Main Methods:

  • Review of clinical characteristics of various fibrotic skin conditions.
  • Analysis of skin histology and disease associations.

Related Experiment Videos

  • Comparison of differential diagnostic criteria for scleroderma mimics.

    • Main Results:

    • Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy), eosinophilic fasciitis (Shulman's syndrome), scleromyxedema, and scleredema present diagnostic challenges.
    • Distinct clinical and histological findings aid in differentiating these from scleroderma.
    • Early recognition by primary care physicians and rheumatologists is essential.

    Conclusions:

    • Promptly distinguishing scleroderma from similar fibrotic conditions improves patient outcomes.
    • Understanding the unique features of nephrogenic systemic fibrosis, eosinophilic fasciitis, scleromyxedema, and scleredema is critical.
    • Rheumatologists require expertise in recognizing these conditions for accurate prognosis and treatment.